PHARMACOKINETIC STUDY OF YOHIMBINE AND ITS PHARMACODYNAMIC EFFECTS ON SALIVARY SECRETION IN PATIENTS TREATED WITH TRICYCLIC ANTIDEPRESSANTS

被引:16
作者
BAGHERI, H
PICAULT, P
SCHMITT, L
HOUIN, G
BERLAN, M
MONTASTRUC, JL
机构
[1] FAC MED TOULOUSE,PHARMACOL MED & CLIN LAB,INSERM,U317,37 ALLEES JULES GUESDE,F-31073 TOULOUSE,FRANCE
[2] UNIV TOULOUSE,SERV HOSP PSYCHIAT,F-31059 TOULOUSE,FRANCE
[3] HOP PURPAN,UNITE PHARMACOCINET CLIN,F-31059 TOULOUSE,FRANCE
关键词
YOHIMBINE; SALIVARY SECRETION; TRICYCLIC ANTIDEPRESSANTS; ALPHA-2-ADRENOCEPTOR ANTAGONISTS; PLASMA CATECHOLAMINES;
D O I
10.1111/j.1365-2125.1994.tb04248.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetic parameters and the time course of the effect after acute oral administration of yohimbine on salivary secretion in patients treated with tricyclic antidepressants were investigated. Yohimbine (10 mg) increased both salivary outflow and plasma noradrenaline levels for 4 h. Pharmacokinetic parameters (t1/2, t(max), C(max) and AUC(exp)) and plasma concentrations of noradrenaline were higher in patients treated with tricyclic antidepressants than in controls. At this dose, yohimbine induced a relatively large number of side effects. A lower dose (4 mg) increased salivary secretion for 3 h without any side effects in patients treated with tricyclic antidepressants but not in healthy volunteers. These data describe an interaction between yohimbine and tricyclic antidepressants and thus show that a relatively low dose (4 mg) of yohimbine could be useful in the treatment of dry mouth due to tricyclic antidepressants.
引用
收藏
页码:93 / 96
页数:4
相关论文
共 21 条
  • [1] EFFECT OF 3 WEEKS TREATMENT WITH YOHIMBINE ON SALIVARY SECRETION IN HEALTHY-VOLUNTEERS AND IN DEPRESSED-PATIENTS TREATED WITH TRICYCLIC ANTIDEPRESSANTS
    BAGHERI, H
    SCHMITT, L
    BERLAN, M
    MONTASTRUC, JL
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (06) : 555 - 558
  • [2] BALDESSARINI RJ, 1990, PHARMACOL BASIS THER, P383
  • [3] PHARMACOLOGICAL PROSPECTS FOR ALPHA-2-ADRENOCEPTOR ANTAGONIST THERAPY
    BERLAN, M
    MONTASTRUC, JL
    LAFONTAN, M
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (07) : 277 - 282
  • [4] ALPHA-2-ADRENOCEPTOR ANTAGONIST POTENCIES OF 2 HYDROXYLATED METABOLITES OF YOHIMBINE
    BERLAN, M
    LEVERGE, R
    GALITZKY, J
    LECORRE, P
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1993, 108 (04) : 927 - 932
  • [5] BERLAN M, 1991, INT J OBESITY, V15, P305
  • [6] BLACKWELL B, 1978, AM J PSYCHIAT, V135, P722
  • [7] CHATELUT E, 1989, BR J CLIN PHARM, V28, P368
  • [8] YOHIMBINE INCREASES SUBMAXILLARY KALLIKREIN RELEASE INTO THE SALIVA IN DOGS - EVIDENCE FOR ALPHA-2-ADRENOCEPTOR-MEDIATED INHIBITION OF CHOLINERGIC PATHWAYS
    GIROLAMI, JP
    BASCANDS, JL
    PECHER, C
    BERLAN, M
    MONTASTRUC, JL
    MONTASTRUC, P
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1991, 102 (02) : 351 - 354
  • [9] GOLDBERG MR, 1983, PHARMACOL REV, V35, P143
  • [10] YOHIMBINE BIOAVAILABILITY IN HUMANS
    GUTHRIE, SK
    HARIHARAN, M
    GRUNHAUS, LJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (04) : 409 - 411